Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose decitabine + G-CSF plus luspatercept to prevent relapse after high-risk AML transplantation
ChiCTR2400082173Phase 3Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Mar 2024
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of decitabine and luspatercept in acute myeloid leukemia (AML), sponsored by Xinqiao Hospital. Primary endpoint: Leukemia relapse. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
decitabineluspatercept
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400082173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082173.